Gamida Cell Ltd (NASDAQ:GMDA) has received a consensus recommendation of “Buy” from the eight ratings firms that are covering the company, MarketBeat.com reports. Eight equities research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have updated their coverage on the stock in the last year is $16.43.
A number of research analysts recently issued reports on the company. Zacks Investment Research upgraded Gamida Cell from a “hold” rating to a “buy” rating and set a $4.00 price target on the stock in a research note on Monday, August 12th. Oppenheimer set a $18.00 price target on Gamida Cell and gave the company a “buy” rating in a report on Wednesday, August 7th. ValuEngine raised Gamida Cell from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Finally, JMP Securities started coverage on Gamida Cell in a report on Friday, September 20th. They set an “outperform” rating and a $16.00 price objective for the company.
A number of institutional investors have recently added to or reduced their stakes in GMDA. Edmond DE Rothschild Holding S.A. purchased a new stake in Gamida Cell during the first quarter valued at about $53,000. Royal Bank of Canada acquired a new position in shares of Gamida Cell during the second quarter worth about $71,000. Bank Hapoalim BM acquired a new stake in Gamida Cell during the second quarter valued at approximately $195,000. EcoR1 Capital LLC bought a new position in shares of Gamida Cell during the second quarter valued at approximately $265,000. Finally, Noked Capital LTD bought a new position in shares of Gamida Cell during the second quarter valued at approximately $1,035,000. 25.86% of the stock is owned by institutional investors.
Gamida Cell (NASDAQ:GMDA) last released its quarterly earnings results on Tuesday, August 6th. The company reported ($0.87) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.32). As a group, sell-side analysts anticipate that Gamida Cell will post -1.16 EPS for the current fiscal year.
About Gamida Cell
Gamida Cell Ltd. is a clinical stage biopharmaceutical company, which engages in the development of cell therapies that are designed to cure cancer and rare serious hematologic diseases. Its products pipeline include NiCord and NAM-NK. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Jerusalem, Israel.
Read More: What is a Leveraged Buyout (LBO)?
Receive News & Ratings for Gamida Cell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gamida Cell and related companies with MarketBeat.com's FREE daily email newsletter.